Back Surgery OK for Opioid-Tolerant Patients

Article

Pain physicians and surgeons have concerns about performing back surgery on patients already taking opioids to control pain. A report from Massachusetts General Hospital researchers shows those concerns appear to be mostly unfounded.

Patients undergoing surgery to treat chronic back or neck pain are often already taking opioids.

The drugs often do not fully eliminate their pain so surgery becomes the next step.

Reporting at the American Society of Interventional Pain Physicians, Padma Gulur, MD and colleagues at Massachusetts General Hospital’s department of anesthesia, critical care and pain medicine in Boston, MA said there has been increasing concern that those on significant amounts of opioids at the time of spinal surgery could have poorer outcomes. Additionally, Gulur wrote in an abstract presented April 11 at the meeting, these patients might need alarmingly high doses of opioids to cope with post-surgical pain.

The group performed a retrospective cohort review of patients undergoing spinal surgery, mostly for pain, from January to June 2013 at Mass General. They compared opioid tolerant patients to controls for opioid use. The groups were compared three times: preoperatively, at discharge and at 6 to 12 months after their surgery.

Those who surgery was due to tumors or cancer, those who died shortly after surgery, and those having repeat surgeries for complications were excluded from the review.

In all there were 626 spinal surgery patients included. Of those 84 were classified as opioid tolerant.

At 6 to 12 months after surgery 71% of the opioid tolerant group were still taking the drugs, compared to only 28% in the control group. But of the opioid tolerant patients, 22 did not need the drugs at discharge, 38 were able to use lower doses and only 22 needed higher doses.

The group concluded that “the majority of patients on opioids preoperatively were on decreased to no opioids postoperatively,” and that the study “may indicate that spinal surgery helps to alleviate back pain in many patients.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.